首页 > 最新文献

Histopathology最新文献

英文 中文
Prognostic values of molecular subtypes and SWI/SNF protein expression in de-differentiated/undifferentiated endometrial carcinoma. 分子亚型和SWI/SNF蛋白表达在去分化/未分化子宫内膜癌中的预后价值
IF 3.9 2区 医学 Q2 CELL BIOLOGY Pub Date : 2025-01-15 DOI: 10.1111/his.15411
Chae Young Shin, Bengul Gokbayrak, Valerie L Tao, Noorah Almadani, Eunice S Li, Rebecca Ho, Felix Kf Kommoss, Jutta Huvila, Derek Chiu, Samuel Leung, Basile Tessier-Cloutier, David G Huntsman, C Blake Gilks, Jessica N McAlpine, Lynn Hoang, Yemin Wang

Aims: Classification and risk stratification of endometrial carcinoma (EC) has transitioned from histopathological features to molecular classification, e.g. the ProMisE classifier, identifying four prognostic subtypes: POLE mutant (POLEmut) with almost no recurrence or disease-specific death events, mismatch repair deficient (MMRd) and no specific molecular profile (NSMP), with intermediate outcome and p53 abnormal (p53abn) with poor outcomes. However, the applicability of molecular classification is unclear in rare but aggressive histotypes of EC, e.g. de-differentiated and undifferentiated endometrial cancers (DD/UDEC). Here, we aim to assembled a cohort of DD/UDEC from a single institution and analysed the prognostic significance of ProMisE molecular subtypes and the expression of SWItch/sucrose non-fermentable (SWI/SNF) chromatin remodelling complex members, previously implicated in the pathogenesis of DD/UDEC.

Methods and results: We accrued 88 DD/UDEC cases, assessed POLE status by Sanger sequencing and performed immunohistochemistry for p53, mismatch repair and SWI/SNF proteins on the tissue microarrays assembled. Assignment of molecular subtypes was possible in 80 tumours; POLE sequencing failed in the remaining eight cases. There were 12 (15%) POLEmut, 44 (55%) MMRd, 14 (17.5%) p53abn and 10 (12.5%) NSMP DD/UDEC. POLEmut DD/UDECs had excellent outcomes, but the other three molecular subtypes all had poor outcomes, with no significant differences among them. The loss of one or more SWI/SNF proteins [AT-rich interactive domain-containing protein 1A (ARID1A), ARID1B, SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 4 (SMARCA4), SMARCA2], observed in 66% (55 of 83) cases, was not of prognostic significance.

Conclusions: These results indicate that all molecular subtypes of DD/UDEC except POLEmut behave in an aggressive fashion. Further study is needed to determine whether these molecular alterations can be targeted with adjuvant therapy, in order to improve outcomes of patients with DD/UDEC.

目的:子宫内膜癌(EC)的分类和风险分层已经从组织病理学特征过渡到分子分类,例如ProMisE分类器,确定了四种预后亚型:POLE突变(POLEmut)几乎没有复发或疾病特异性死亡事件,错配修复缺陷(MMRd)和无特异性分子谱(NSMP),预后中等,p53异常(p53abn)预后较差。然而,分子分类在罕见但侵袭性的EC组织类型中的适用性尚不清楚,例如去分化和未分化子宫内膜癌(DD/UDEC)。在这里,我们的目标是来自单一机构的DD/UDEC队列,并分析ProMisE分子亚型和SWItch/蔗糖不可发酵(SWI/SNF)染色质重塑复合物成员的表达的预后意义,这些成员先前与DD/UDEC的发病机制有关。方法和结果:我们收集了88例DD/UDEC病例,通过Sanger测序评估POLE状态,并在组装的组织微阵列上对p53、错配修复和SWI/SNF蛋白进行免疫组化检测。在80例肿瘤中可以确定分子亚型;其余8例的POLE测序失败。POLEmut 12例(15%),MMRd 44例(55%),p53abn 14例(17.5%),NSMP DD/UDEC 10例(12.5%)。POLEmut DD/ udec预后较好,其他3种分子亚型预后均较差,且差异无统计学意义。66%(83例中有55例)的SWI/SNF蛋白缺失一个或多个SWI/SNF蛋白[富含at的相互作用结构域蛋白1A (ARID1A)、ARID1B、SWI/SNF相关、基质相关、依赖于动作蛋白的染色质调节因子A亚家族成员4 (SMARCA4)、SMARCA2],但不具有预后意义。结论:这些结果表明,除了POLEmut外,DD/UDEC的所有分子亚型都表现出侵袭性。为了改善DD/UDEC患者的预后,需要进一步的研究来确定这些分子改变是否可以靶向辅助治疗。
{"title":"Prognostic values of molecular subtypes and SWI/SNF protein expression in de-differentiated/undifferentiated endometrial carcinoma.","authors":"Chae Young Shin, Bengul Gokbayrak, Valerie L Tao, Noorah Almadani, Eunice S Li, Rebecca Ho, Felix Kf Kommoss, Jutta Huvila, Derek Chiu, Samuel Leung, Basile Tessier-Cloutier, David G Huntsman, C Blake Gilks, Jessica N McAlpine, Lynn Hoang, Yemin Wang","doi":"10.1111/his.15411","DOIUrl":"https://doi.org/10.1111/his.15411","url":null,"abstract":"<p><strong>Aims: </strong>Classification and risk stratification of endometrial carcinoma (EC) has transitioned from histopathological features to molecular classification, e.g. the ProMisE classifier, identifying four prognostic subtypes: POLE mutant (POLEmut) with almost no recurrence or disease-specific death events, mismatch repair deficient (MMRd) and no specific molecular profile (NSMP), with intermediate outcome and p53 abnormal (p53abn) with poor outcomes. However, the applicability of molecular classification is unclear in rare but aggressive histotypes of EC, e.g. de-differentiated and undifferentiated endometrial cancers (DD/UDEC). Here, we aim to assembled a cohort of DD/UDEC from a single institution and analysed the prognostic significance of ProMisE molecular subtypes and the expression of SWItch/sucrose non-fermentable (SWI/SNF) chromatin remodelling complex members, previously implicated in the pathogenesis of DD/UDEC.</p><p><strong>Methods and results: </strong>We accrued 88 DD/UDEC cases, assessed POLE status by Sanger sequencing and performed immunohistochemistry for p53, mismatch repair and SWI/SNF proteins on the tissue microarrays assembled. Assignment of molecular subtypes was possible in 80 tumours; POLE sequencing failed in the remaining eight cases. There were 12 (15%) POLEmut, 44 (55%) MMRd, 14 (17.5%) p53abn and 10 (12.5%) NSMP DD/UDEC. POLEmut DD/UDECs had excellent outcomes, but the other three molecular subtypes all had poor outcomes, with no significant differences among them. The loss of one or more SWI/SNF proteins [AT-rich interactive domain-containing protein 1A (ARID1A), ARID1B, SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 4 (SMARCA4), SMARCA2], observed in 66% (55 of 83) cases, was not of prognostic significance.</p><p><strong>Conclusions: </strong>These results indicate that all molecular subtypes of DD/UDEC except POLEmut behave in an aggressive fashion. Further study is needed to determine whether these molecular alterations can be targeted with adjuvant therapy, in order to improve outcomes of patients with DD/UDEC.</p>","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Threonine and tyrosine kinase (TTK) mRNA and protein expression in breast cancer; prognostic significance in the neoadjuvant setting. 乳腺癌组织中苏氨酸和酪氨酸激酶(TTK) mRNA和蛋白的表达新辅助治疗的预后意义。
IF 3.9 2区 医学 Q2 CELL BIOLOGY Pub Date : 2025-01-07 DOI: 10.1111/his.15399
Abrar Ashi, Aeshah A Awaji, Jacquelyn Bond, Colin A Johnson, Abeer M Shaaban, Sandra M Bell

Aims: Threonine and tyrosine kinase (TTK) is up-regulated in triple-negative breast cancer (TNBC), yet its expression in patients undergoing neoadjuvant chemotherapy (NACT) remains unexplored. This investigation aims to assess TTK protein expression in treatment-naïve pre-treatment cores and paired pre- and post-NACT breast cancer (BC) cohorts, as well as its correlation with microcephaly 1 (MCPH1) protein expression.

Methods and results: Transcriptomic data were sourced from the Gene Expression Omnibus microarray database for mRNA expression analysis. TTK protein expression was evaluated using immunohistochemistry staining, employing receiver operating characteristic curve analysis to determine an optimal TTK expression cut-off point. The association between TTK expression, clinicopathological parameters and survival outcomes was examined. Additionally, MCPH1 protein expression was assessed in a pilot study. Analysis revealed a significantly elevated TTK mRNA expression in BC tissue compared to normal breast tissue, with high TTK mRNA levels predicting reduced overall survival. Notably, TTK protein expression increased significantly post-NACT in a paired cohort. Conversely, decreased TTK protein expression pre-NACT was correlated with improved overall survival.

Conclusions: High TTK and low MCPH1 protein expression was significantly correlated, highlighting TTK's potential as a biomarker for BC and a therapeutic target for MCPH1-deficient cancer cells.

目的:苏氨酸和酪氨酸激酶(TTK)在三阴性乳腺癌(TNBC)中上调,但其在新辅助化疗(NACT)患者中的表达尚不清楚。这项研究旨在评估TTK蛋白在treatment-naïve治疗前核心和配对的nact前和后乳腺癌(BC)队列中的表达,以及其与小头畸形1 (MCPH1)蛋白表达的相关性。方法和结果:转录组学数据来源于基因表达Omnibus微阵列数据库,用于mRNA表达分析。采用免疫组织化学染色评估TTK蛋白表达,采用受体工作特征曲线分析确定最佳TTK表达截止点。研究了TTK表达、临床病理参数和生存结果之间的关系。此外,在一项初步研究中评估了MCPH1蛋白的表达。分析显示,与正常乳腺组织相比,BC组织中TTK mRNA表达显著升高,TTK mRNA水平高预示总生存率降低。值得注意的是,在配对队列中,TTK蛋白表达在nact后显著增加。相反,nact前TTK蛋白表达的降低与总生存率的提高相关。结论:高TTK和低MCPH1蛋白表达显著相关,突出了TTK作为BC的生物标志物和MCPH1缺陷癌细胞的治疗靶点的潜力。
{"title":"Threonine and tyrosine kinase (TTK) mRNA and protein expression in breast cancer; prognostic significance in the neoadjuvant setting.","authors":"Abrar Ashi, Aeshah A Awaji, Jacquelyn Bond, Colin A Johnson, Abeer M Shaaban, Sandra M Bell","doi":"10.1111/his.15399","DOIUrl":"https://doi.org/10.1111/his.15399","url":null,"abstract":"<p><strong>Aims: </strong>Threonine and tyrosine kinase (TTK) is up-regulated in triple-negative breast cancer (TNBC), yet its expression in patients undergoing neoadjuvant chemotherapy (NACT) remains unexplored. This investigation aims to assess TTK protein expression in treatment-naïve pre-treatment cores and paired pre- and post-NACT breast cancer (BC) cohorts, as well as its correlation with microcephaly 1 (MCPH1) protein expression.</p><p><strong>Methods and results: </strong>Transcriptomic data were sourced from the Gene Expression Omnibus microarray database for mRNA expression analysis. TTK protein expression was evaluated using immunohistochemistry staining, employing receiver operating characteristic curve analysis to determine an optimal TTK expression cut-off point. The association between TTK expression, clinicopathological parameters and survival outcomes was examined. Additionally, MCPH1 protein expression was assessed in a pilot study. Analysis revealed a significantly elevated TTK mRNA expression in BC tissue compared to normal breast tissue, with high TTK mRNA levels predicting reduced overall survival. Notably, TTK protein expression increased significantly post-NACT in a paired cohort. Conversely, decreased TTK protein expression pre-NACT was correlated with improved overall survival.</p><p><strong>Conclusions: </strong>High TTK and low MCPH1 protein expression was significantly correlated, highlighting TTK's potential as a biomarker for BC and a therapeutic target for MCPH1-deficient cancer cells.</p>","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Further confirmation of a highly prognostic grading scheme based upon tumour budding and cell cluster size in cervical squamous cell carcinoma. 进一步确认基于宫颈鳞状细胞癌肿瘤出芽和细胞簇大小的高度预后分级方案。
IF 3.9 2区 医学 Q2 CELL BIOLOGY Pub Date : 2024-12-27 DOI: 10.1111/his.15404
Wenwen Zhang, Yiling Song, Haiyan Shi, Bingjian Lu

Aims: Our study aimed to further confirm the clinical significance of the tumour budding activity and cell nest size-based (TBNS) grading scheme in cervical squamous cell carcinomas (SCC).

Methods and results: We applied the TBNS system to assess the prognostic value in an institutional cohort of well-annotated cervical SCC consisting of 312 consecutive cases with surgical resection, no neoadjuvant chemotherapy and higher than stage pT1a. We found that high budding activity, single cell and TBNS grade 3 were more frequently associated with a decreased overall survival (OS) time and disease-free survival (DFS) time (P < 0.001) and several other clinicopathological factors, including lymphovascular space invasion, lymph node metastasis, advanced Federation of Gynecology and Obstetrics (FIGO) stage and deep invasion of the cervical wall (> 2/3) (P < 0.05). On multivariate analysis, TBNS grade 3 was an adverse indicator for OS and DFS independently of age, invasion of the cervical wall and FIGO stage (P < 0.05). By comparison, the conventional three-tiered grading system was not associated with OS and DFS in cervical SCC (P > 0.05).

Conclusions: Our study further confirms that the TBNS grading scheme is robust in prognostic assessment in cervical SCC that outperforms the conventional three-tiered grading system. It is applicable to add TBNS grade into routine diagnostic practice.

目的:本研究旨在进一步证实宫颈鳞状细胞癌(SCC)肿瘤出芽活性及基于细胞巢大小(TBNS)分级方案的临床意义。方法和结果:我们应用TBNS系统对312例连续手术切除、未新辅助化疗且pT1a期以上的宫颈鳞状细胞癌的机构队列进行预后评估。我们发现高出芽活性、单细胞和TBNS 3级与总生存(OS)时间和无病生存(DFS)时间的缩短更为频繁(P 2/3) (P 0.05)。结论:我们的研究进一步证实了TBNS分级方案在宫颈鳞状细胞癌的预后评估中是可靠的,优于传统的三级分级系统。在常规诊断中增加TBNS分级是可行的。
{"title":"Further confirmation of a highly prognostic grading scheme based upon tumour budding and cell cluster size in cervical squamous cell carcinoma.","authors":"Wenwen Zhang, Yiling Song, Haiyan Shi, Bingjian Lu","doi":"10.1111/his.15404","DOIUrl":"https://doi.org/10.1111/his.15404","url":null,"abstract":"<p><strong>Aims: </strong>Our study aimed to further confirm the clinical significance of the tumour budding activity and cell nest size-based (TBNS) grading scheme in cervical squamous cell carcinomas (SCC).</p><p><strong>Methods and results: </strong>We applied the TBNS system to assess the prognostic value in an institutional cohort of well-annotated cervical SCC consisting of 312 consecutive cases with surgical resection, no neoadjuvant chemotherapy and higher than stage pT1a. We found that high budding activity, single cell and TBNS grade 3 were more frequently associated with a decreased overall survival (OS) time and disease-free survival (DFS) time (P < 0.001) and several other clinicopathological factors, including lymphovascular space invasion, lymph node metastasis, advanced Federation of Gynecology and Obstetrics (FIGO) stage and deep invasion of the cervical wall (> 2/3) (P < 0.05). On multivariate analysis, TBNS grade 3 was an adverse indicator for OS and DFS independently of age, invasion of the cervical wall and FIGO stage (P < 0.05). By comparison, the conventional three-tiered grading system was not associated with OS and DFS in cervical SCC (P > 0.05).</p><p><strong>Conclusions: </strong>Our study further confirms that the TBNS grading scheme is robust in prognostic assessment in cervical SCC that outperforms the conventional three-tiered grading system. It is applicable to add TBNS grade into routine diagnostic practice.</p>","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk prediction criteria for the primary hepatic perivascular epithelioid cell tumour family, including angiomyolipoma: analysis of 132 cases with a literature review. 包括血管平滑肌脂肪瘤在内的原发性肝血管周围上皮样细胞肿瘤家族的风险预测标准:132例分析并文献复习
IF 3.9 2区 医学 Q2 CELL BIOLOGY Pub Date : 2024-12-27 DOI: 10.1111/his.15405
Youngeun Yoo, Jihun Kim, In Hye Song

Aims: The hepatic perivascular epithelioid cell tumour (PEComa), including angiomyolipoma, exhibits diverse morphology and clinical behaviour; however, its prognostic features remain undefined. This study aimed to investigate its histological features and prognostic factors.

Methods and results: In total, 132 patients were included. Clinical data and histopathological slides were assessed along with the p53 and Ki-67 immunohistochemistry. Targeted next-generation sequencing was performed in three cases. Based on the histologic subtypes, 7 (10%), 36 (51%), 13 (18%), and 15 (21%) patients were classified as inflammatory angiomyolipoma, conventional angiomyolipoma, epithelioid angiomyolipoma, and PEComa not otherwise specified (NOS), respectively, among 71 patients who underwent surgical resection. We proposed the risk prediction criteria after defining primary tumour size ≥7 cm, infiltrative border, mitotic rate >1/10 mm2, necrosis, vascular invasion, and PEComa NOS as worrisome features, as follows: high-risk: ≥3 worrisome features; intermediate-risk: 1-2 features; low-risk: none of the features. Applying these criteria, 4 (6%), 31 (44%), and 36 (51%) patients were classified into high-, intermediate-, and low-risk groups, respectively. One patient each in the high-risk (25%) and intermediate-risk (3%) groups developed peritoneal metastases and intrahepatic recurrence, respectively, whereas none in the low-risk group showed disease progression. A literature review of clinically malignant hepatic PEComa family tumours was conducted, and upon application of our criteria, 62% (16/26) of the patients were classified as high-risk and 35% (9/26) as intermediate- or high-risk.

Conclusion: Our risk prediction criteria can effectively predict the clinical outcomes in primary hepatic PEComa.

目的:肝血管周围上皮样细胞瘤(PEComa),包括血管平滑肌脂肪瘤,表现出不同的形态和临床行为;然而,其预后特征仍不明确。本研究旨在探讨其组织学特征及预后因素。方法与结果:共纳入132例患者。临床资料和组织病理学切片与p53和Ki-67免疫组织化学进行评估。3例进行了靶向下一代测序。根据组织学亚型,71例行手术切除的患者分别有7例(10%)、36例(51%)、13例(18%)和15例(21%)分为炎性血管平滑肌脂肪瘤、常规血管平滑肌脂肪瘤、上皮样血管平滑肌脂肪瘤和无特异性PEComa (NOS)。我们将原发肿瘤大小≥7 cm、浸润边界、有丝分裂率bb0 1/10 mm2、坏死、血管浸润、PEComa NOS等定义为令人担忧的特征,提出了以下风险预测标准:高风险:≥3个令人担忧的特征;中度风险:1-2个特征;低风险:没有这些特征。应用这些标准,分别有4例(6%)、31例(44%)和36例(51%)患者被分为高危、中危和低危组。高危组(25%)和中危组(3%)各有1例患者出现腹膜转移和肝内复发,而低危组中没有患者出现疾病进展。我们对临床恶性肝PEComa家族肿瘤进行了文献回顾,根据我们的标准,62%(16/26)的患者被归为高危,35%(9/26)的患者被归为中高危。结论:我们的风险预测标准能有效预测原发性肝PEComa的临床预后。
{"title":"Risk prediction criteria for the primary hepatic perivascular epithelioid cell tumour family, including angiomyolipoma: analysis of 132 cases with a literature review.","authors":"Youngeun Yoo, Jihun Kim, In Hye Song","doi":"10.1111/his.15405","DOIUrl":"https://doi.org/10.1111/his.15405","url":null,"abstract":"<p><strong>Aims: </strong>The hepatic perivascular epithelioid cell tumour (PEComa), including angiomyolipoma, exhibits diverse morphology and clinical behaviour; however, its prognostic features remain undefined. This study aimed to investigate its histological features and prognostic factors.</p><p><strong>Methods and results: </strong>In total, 132 patients were included. Clinical data and histopathological slides were assessed along with the p53 and Ki-67 immunohistochemistry. Targeted next-generation sequencing was performed in three cases. Based on the histologic subtypes, 7 (10%), 36 (51%), 13 (18%), and 15 (21%) patients were classified as inflammatory angiomyolipoma, conventional angiomyolipoma, epithelioid angiomyolipoma, and PEComa not otherwise specified (NOS), respectively, among 71 patients who underwent surgical resection. We proposed the risk prediction criteria after defining primary tumour size ≥7 cm, infiltrative border, mitotic rate >1/10 mm<sup>2</sup>, necrosis, vascular invasion, and PEComa NOS as worrisome features, as follows: high-risk: ≥3 worrisome features; intermediate-risk: 1-2 features; low-risk: none of the features. Applying these criteria, 4 (6%), 31 (44%), and 36 (51%) patients were classified into high-, intermediate-, and low-risk groups, respectively. One patient each in the high-risk (25%) and intermediate-risk (3%) groups developed peritoneal metastases and intrahepatic recurrence, respectively, whereas none in the low-risk group showed disease progression. A literature review of clinically malignant hepatic PEComa family tumours was conducted, and upon application of our criteria, 62% (16/26) of the patients were classified as high-risk and 35% (9/26) as intermediate- or high-risk.</p><p><strong>Conclusion: </strong>Our risk prediction criteria can effectively predict the clinical outcomes in primary hepatic PEComa.</p>","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HIV, measles, and syphilis: histopathologic characteristics of lymphatic system involvement of three reemerging infectious diseases. HIV、麻疹和梅毒:三种复发性传染病淋巴系统累及的组织病理学特征。
IF 3.9 2区 医学 Q2 CELL BIOLOGY Pub Date : 2024-12-27 DOI: 10.1111/his.15408
Aaron Auerbach, John J Schmieg, Mary Klassen, Ann Nelson, Nadine S Aguilera

The resurgence of measles, syphilis, and HIV presents a significant threat to global health, especially in the wake of the COVID-19 pandemic. These three infections involve lymph nodes and have unique pathologic findings in lymph nodes. We explore the pathological and clinical characteristics of these infections, focusing on their involvement of lymph nodes and their pathologic diagnosis in lymph node specimens. For HIV, lymph nodes are sites of viral replication and reservoirs, and the disease demonstrates multiple patterns within lymph nodes. The recent increase in measles, due in part to declining vaccination rates, signals the need for pathologists to be able to identify the characteristic Warthin-Finkeldey cells present in lymph node specimens. Syphilis, a reemerging sexually transmitted infection, often presents with lymphadenopathy and can mimic other conditions, complicating clinical diagnosis. By revisiting well-established findings and presenting new insights into the histopathological changes within lymphoid tissues, this review provides essential knowledge for pathologists and clinicians to improve diagnostic accuracy and treatment outcomes.

麻疹、梅毒和艾滋病毒的死灰复燃对全球健康构成重大威胁,特别是在2019冠状病毒病大流行之后。这三种感染涉及淋巴结,在淋巴结有独特的病理表现。我们探讨这些感染的病理和临床特点,重点是淋巴结的参与和淋巴结标本的病理诊断。对于艾滋病毒来说,淋巴结是病毒复制和储存的场所,这种疾病在淋巴结内表现出多种模式。最近麻疹病例的增加,部分原因是疫苗接种率下降,这表明病理学家需要能够识别淋巴结标本中存在的特征性Warthin-Finkeldey细胞。梅毒是一种再次出现的性传播感染,通常表现为淋巴结病,并可模仿其他疾病,使临床诊断复杂化。通过回顾已有的发现,并对淋巴组织内的组织病理学变化提出新的见解,本综述为病理学家和临床医生提高诊断准确性和治疗效果提供了必要的知识。
{"title":"HIV, measles, and syphilis: histopathologic characteristics of lymphatic system involvement of three reemerging infectious diseases.","authors":"Aaron Auerbach, John J Schmieg, Mary Klassen, Ann Nelson, Nadine S Aguilera","doi":"10.1111/his.15408","DOIUrl":"https://doi.org/10.1111/his.15408","url":null,"abstract":"<p><p>The resurgence of measles, syphilis, and HIV presents a significant threat to global health, especially in the wake of the COVID-19 pandemic. These three infections involve lymph nodes and have unique pathologic findings in lymph nodes. We explore the pathological and clinical characteristics of these infections, focusing on their involvement of lymph nodes and their pathologic diagnosis in lymph node specimens. For HIV, lymph nodes are sites of viral replication and reservoirs, and the disease demonstrates multiple patterns within lymph nodes. The recent increase in measles, due in part to declining vaccination rates, signals the need for pathologists to be able to identify the characteristic Warthin-Finkeldey cells present in lymph node specimens. Syphilis, a reemerging sexually transmitted infection, often presents with lymphadenopathy and can mimic other conditions, complicating clinical diagnosis. By revisiting well-established findings and presenting new insights into the histopathological changes within lymphoid tissues, this review provides essential knowledge for pathologists and clinicians to improve diagnostic accuracy and treatment outcomes.</p>","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expression of claudin-18.2 in cholangiocarcinoma: a comprehensive immunohistochemical analysis from a German tertiary centre claudin-18.2在胆管癌中的表达:来自德国三级中心的全面免疫组织化学分析。
IF 3.9 2区 医学 Q2 CELL BIOLOGY Pub Date : 2024-12-27 DOI: 10.1111/his.15407
Maximilian N Kinzler, Steffen Gretser, Falko Schulze, Katrin Bankov, Nada Abedin, Wolf O Bechstein, Fabian Finkelmeier, Stefan Zeuzem, Henning Reis, Peter J. Wild, Dirk Walter

Aims

Anti-claudin-18.2 (CLDN18.2) therapy was recently approved for the treatment of gastric or gastro-oesophageal junction adenocarcinoma. The aim of the present study was to investigate the expression of CLDN18.2 in cholangiocarcinoma (CCA) to determine whether there is a subgroup of patients who might also benefit from anti-CLDN18.2 therapy.

Methods and results

A tissue microarray (TMA) cohort of all CCA patients who underwent surgical resection with curative intent between August 2005 and December 2021 at University Hospital Frankfurt were immunohistochemically evaluated using the VENTANA® CLDN18 (43-14A) antibody. Tumour positivity for CLDN18.2 was determined as follows: ≥ 75% of tumour cells with moderate-to-strong CLDN18 membranous staining. In total, 160 patients with surgically resected CCA were suitable for immunohistochemistry (IHC) analysis. Of the patients, 13.1% (n = 21) showed moderate to strong membranous staining of VENTANA® CLDN18 antibody, while 86.9% (n = 139) were negative. Subtype analysis revealed strong differences in CLDN18 expression. Positive staining of CLDN18 could be observed in 26.5% (n = nine of 34) and 7.4% (n = seven of 95) of the perihilar (pCCA) and intrahepatic (iCCA) subgroup, respectively. CCA patients with CLDN18 expression had a more frequently intraoperative finding of distant metastasis (P = 0.002), lymph node metastasis (P = 0.008) and positive perineural invasion (Pn1) status (P = 0.022).

Conclusions

The present study suggests that a subset of patients with CCA exhibited a marked expression of CLDN18.2. These findings underline the need to perform a clinical study evaluating the efficacy of anti-CLDN18.2 therapy in patients suffering from CCA.

目的:抗CLDN18.2 (CLDN18.2)疗法最近被批准用于治疗胃或胃-食管交界处腺癌。本研究的目的是研究CLDN18.2在胆管癌(CCA)中的表达,以确定是否存在一个亚组患者也可能从抗CLDN18.2治疗中获益。方法和结果:2005年8月至2021年12月在法兰克福大学医院接受手术切除的所有CCA患者的组织微阵列(TMA)队列使用VENTANA®CLDN18 (43-14A)抗体进行免疫组织化学评估。CLDN18.2的肿瘤阳性确定如下:≥75%的肿瘤细胞具有中至强CLDN18膜染色。总共有160例手术切除的CCA患者适合进行免疫组织化学(IHC)分析。13.1% (n = 21)的患者显示VENTANA®CLDN18抗体中至强膜性染色,86.9% (n = 139)的患者呈阴性。亚型分析显示CLDN18表达存在明显差异。肝门周(pCCA)亚组和肝内(iCCA)亚组CLDN18阳性分别为26.5% (n = 9 / 34)和7.4% (n = 7 / 95)。CLDN18表达的CCA患者术中发现远端转移(P = 0.002)、淋巴结转移(P = 0.008)和周围神经浸润(Pn1)阳性(P = 0.022)的频率更高。结论:目前的研究表明,一部分CCA患者表现出明显的CLDN18.2表达。这些发现强调需要进行临床研究,评估抗cldn18.2治疗对CCA患者的疗效。
{"title":"Expression of claudin-18.2 in cholangiocarcinoma: a comprehensive immunohistochemical analysis from a German tertiary centre","authors":"Maximilian N Kinzler,&nbsp;Steffen Gretser,&nbsp;Falko Schulze,&nbsp;Katrin Bankov,&nbsp;Nada Abedin,&nbsp;Wolf O Bechstein,&nbsp;Fabian Finkelmeier,&nbsp;Stefan Zeuzem,&nbsp;Henning Reis,&nbsp;Peter J. Wild,&nbsp;Dirk Walter","doi":"10.1111/his.15407","DOIUrl":"10.1111/his.15407","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Anti-claudin-18.2 (CLDN18.2) therapy was recently approved for the treatment of gastric or gastro-oesophageal junction adenocarcinoma. The aim of the present study was to investigate the expression of CLDN18.2 in cholangiocarcinoma (CCA) to determine whether there is a subgroup of patients who might also benefit from anti-CLDN18.2 therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and results</h3>\u0000 \u0000 <p>A tissue microarray (TMA) cohort of all CCA patients who underwent surgical resection with curative intent between August 2005 and December 2021 at University Hospital Frankfurt were immunohistochemically evaluated using the VENTANA<sup>®</sup> CLDN18 (43-14A) antibody. Tumour positivity for CLDN18.2 was determined as follows: ≥ 75% of tumour cells with moderate-to-strong CLDN18 membranous staining. In total, 160 patients with surgically resected CCA were suitable for immunohistochemistry (IHC) analysis. Of the patients, 13.1% (<i>n</i> = 21) showed moderate to strong membranous staining of VENTANA<sup>®</sup> CLDN18 antibody, while 86.9% (<i>n</i> = 139) were negative. Subtype analysis revealed strong differences in CLDN18 expression. Positive staining of CLDN18 could be observed in 26.5% (<i>n</i> = nine of 34) and 7.4% (<i>n</i> = seven of 95) of the perihilar (pCCA) and intrahepatic (iCCA) subgroup, respectively. CCA patients with CLDN18 expression had a more frequently intraoperative finding of distant metastasis (<i>P</i> = 0.002), lymph node metastasis (<i>P</i> = 0.008) and positive perineural invasion (Pn1) status (<i>P</i> = 0.022).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The present study suggests that a subset of patients with CCA exhibited a marked expression of CLDN18.2. These findings underline the need to perform a clinical study evaluating the efficacy of anti-CLDN18.2 therapy in patients suffering from CCA.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":"86 4","pages":"640-646"},"PeriodicalIF":3.9,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/his.15407","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic interobserver variability of atypia assessment in columnar cell lesions among a group of expert breast pathologists in the United Kingdom and the Republic of Ireland, on behalf of the UK national coordinating committee for breast pathology. 英国和爱尔兰共和国的一组乳腺病理学专家代表英国国家乳腺病理学协调委员会对柱状细胞病变非典型性评估的诊断观察者间可变性进行了研究。
IF 3.9 2区 医学 Q2 CELL BIOLOGY Pub Date : 2024-12-20 DOI: 10.1111/his.15402
Soha El Sheikh, Mohamed A Mansour, Elena Provenzano, Abeer Shaaban, Andrew Lee, Yasmeen Mir, Rebecca McMillan-Slater, Pauline Carder, Silvana Di Palma, Clinton Boyd, Purnima Makhija, Madhuri Warren, Susan Pritchard, Rahul Deb, Ian Ellis, Emad Rakha, Cecily Quinn, Sarah Pinder

Aims: Atypical ductal hyperplasia and flat epithelial atypia (FEA) have defined diagnostic criteria, yet there is variation in the interpretation of these criteria, particularly when the atypia is present in a background of columnar cell lesions (CCLs). This study focuses upon cases which are especially challenging or difficult to classify reproducibly according to existing criteria.

Methods and results: Thirteen breast pathology experts were asked to classify 10 challenging cases with CLLs as atypical or non-atypical. Interobserver agreement was calculated. After two consensus meetings, which explored the morphological features underlying the decision, the cases were reassessed. Finally, a photomontage was compiled as a visual aid for practising pathologists representing a range of straightforward cases and others where subjective interpretation causes disagreement within current diagnostic criteria. Overall interobserver agreement and pairwise pathologist agreement coefficients were both in the fair range (κ = 0.22 and κ = 0.3-0.4, respectively). This improved to moderate or substantial agreement (κ = 0.6-0.8) after two consensus meetings. The most controversial cases were atypical cases that lacked the regular rounded nuclei of FEA, and non-atypical cases that had florid architectural changes bordering on architectural atypia.

Conclusion: Among expert breast pathologists, interobserver agreement in the diagnosis of atypia in CCLs was higher in cases with classical features of FEA. Consensus was difficult to achieve if nuclear or architectural atypia fell outside the classical definition of FEA, suggesting that this category does not encompass the range of low-grade cytological atypia in CLLs. This study provides rationale for expanding the definition of atypia in CCLs other than FEA.

目的:非典型导管增生和扁平上皮异型性(FEA)有明确的诊断标准,但对这些标准的解释存在差异,特别是当异型性出现在柱状细胞病变(CCLs)背景时。本研究的重点是那些特别具有挑战性或难以根据现有标准进行可重复性分类的病例。方法和结果:13名乳腺病理学专家被要求将10例具有挑战性的cll分为非典型或非典型。计算了观察员间的一致意见。经过两次协商一致的会议,探讨了决定背后的形态学特征,重新评估了这些病例。最后,编制了一个蒙太奇,作为执业病理学家的视觉辅助,代表了一系列简单的病例和其他主观解释导致当前诊断标准不一致的病例。整体观察者间一致性和病理一致性系数均在合理范围内(κ = 0.22和κ = 0.3-0.4)。在两次共识会议后,这一结果改善为中度或实质性一致(κ = 0.6-0.8)。最具争议的病例是缺乏规则圆形FEA核的非典型病例,以及具有接近非典型建筑的华丽建筑变化的非典型病例。结论:在乳腺病理学专家中,具有典型FEA特征的ccl非典型性诊断一致性较高。如果核非典型性或建筑非典型性超出FEA的经典定义,则很难达成共识,这表明这一类别不包括cll中低级别细胞学非典型性的范围。本研究为扩展FEA以外的ccl非典型性定义提供了理论依据。
{"title":"Diagnostic interobserver variability of atypia assessment in columnar cell lesions among a group of expert breast pathologists in the United Kingdom and the Republic of Ireland, on behalf of the UK national coordinating committee for breast pathology.","authors":"Soha El Sheikh, Mohamed A Mansour, Elena Provenzano, Abeer Shaaban, Andrew Lee, Yasmeen Mir, Rebecca McMillan-Slater, Pauline Carder, Silvana Di Palma, Clinton Boyd, Purnima Makhija, Madhuri Warren, Susan Pritchard, Rahul Deb, Ian Ellis, Emad Rakha, Cecily Quinn, Sarah Pinder","doi":"10.1111/his.15402","DOIUrl":"https://doi.org/10.1111/his.15402","url":null,"abstract":"<p><strong>Aims: </strong>Atypical ductal hyperplasia and flat epithelial atypia (FEA) have defined diagnostic criteria, yet there is variation in the interpretation of these criteria, particularly when the atypia is present in a background of columnar cell lesions (CCLs). This study focuses upon cases which are especially challenging or difficult to classify reproducibly according to existing criteria.</p><p><strong>Methods and results: </strong>Thirteen breast pathology experts were asked to classify 10 challenging cases with CLLs as atypical or non-atypical. Interobserver agreement was calculated. After two consensus meetings, which explored the morphological features underlying the decision, the cases were reassessed. Finally, a photomontage was compiled as a visual aid for practising pathologists representing a range of straightforward cases and others where subjective interpretation causes disagreement within current diagnostic criteria. Overall interobserver agreement and pairwise pathologist agreement coefficients were both in the fair range (κ = 0.22 and κ = 0.3-0.4, respectively). This improved to moderate or substantial agreement (κ = 0.6-0.8) after two consensus meetings. The most controversial cases were atypical cases that lacked the regular rounded nuclei of FEA, and non-atypical cases that had florid architectural changes bordering on architectural atypia.</p><p><strong>Conclusion: </strong>Among expert breast pathologists, interobserver agreement in the diagnosis of atypia in CCLs was higher in cases with classical features of FEA. Consensus was difficult to achieve if nuclear or architectural atypia fell outside the classical definition of FEA, suggesting that this category does not encompass the range of low-grade cytological atypia in CLLs. This study provides rationale for expanding the definition of atypia in CCLs other than FEA.</p>","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ossifying fibromyxoid tumours with lipomatous and cartilaginous differentiation: A diagnostic pitfall. 骨化纤维黏液样肿瘤伴脂肪瘤和软骨分化:一个诊断缺陷。
IF 3.9 2区 医学 Q2 CELL BIOLOGY Pub Date : 2024-12-20 DOI: 10.1111/his.15396
Natálie Klubíčková, Steven Billings, Josephine K T Dermawan, Jeremy F Molligan, Karen Fritchie

Aims: Ossifying fibromyxoid tumour is a rare mesenchymal neoplasm predominantly affecting adults characterised by a multinodular growth pattern and the presence of a fibrous pseudocapsule with areas of ossification. Prompted by the recognition of a non-ossifying ossifying fibromyxoid tumour with lipomatous differentiation which caused diagnostic difficulty, we sought to further explore cases of ossifying fibromyxoid tumour with non-osseous heterologous elements.

Methods and results: A search of our institutional and consultation archives revealed three additional cases that demonstrated lipomatous components and two cases with cartilaginous differentiation. RNA-sequencing revealed fusions involving PHF1 (n = 4) or EPC1 (n = 1) in all (five of five) cases tested, including EPC1::PHC1 and JAZF1::PHF1 fusions, which have not been reported before in ossifying fibromyxoid tumour.

Conclusion: These six cases expand the histomorphological spectrum of ossifying fibromyxoid tumour, introducing lipomatous differentiation as a hitherto undocumented feature. Awareness of these rare variants will ensure appropriate diagnosis and clinical management.

目的:骨化性纤维黏液样肿瘤是一种罕见的间质肿瘤,主要影响成人,其特征是多结节生长模式和纤维假包膜的存在,并伴有骨化区。由于认识到非骨化性骨化性纤维黏液样肿瘤伴脂肪瘤分化,导致诊断困难,我们寻求进一步探讨骨化性纤维黏液样肿瘤伴非骨性异源元素的病例。方法和结果:对我们的机构和咨询档案进行了搜索,发现了另外3例脂肪瘤成分和2例软骨分化。rna测序显示,在所有(5例中的5例)检测的病例中,均有涉及PHF1 (n = 4)或EPC1 (n = 1)的融合,包括EPC1::PHC1和JAZF1::PHF1融合,这些融合在骨化纤维黏液样肿瘤中未见报道。结论:这6例扩大了骨化纤维黏液样瘤的组织形态学谱,引入了脂肪瘤分化作为一个迄今未记载的特征。了解这些罕见的变异将确保适当的诊断和临床管理。
{"title":"Ossifying fibromyxoid tumours with lipomatous and cartilaginous differentiation: A diagnostic pitfall.","authors":"Natálie Klubíčková, Steven Billings, Josephine K T Dermawan, Jeremy F Molligan, Karen Fritchie","doi":"10.1111/his.15396","DOIUrl":"https://doi.org/10.1111/his.15396","url":null,"abstract":"<p><strong>Aims: </strong>Ossifying fibromyxoid tumour is a rare mesenchymal neoplasm predominantly affecting adults characterised by a multinodular growth pattern and the presence of a fibrous pseudocapsule with areas of ossification. Prompted by the recognition of a non-ossifying ossifying fibromyxoid tumour with lipomatous differentiation which caused diagnostic difficulty, we sought to further explore cases of ossifying fibromyxoid tumour with non-osseous heterologous elements.</p><p><strong>Methods and results: </strong>A search of our institutional and consultation archives revealed three additional cases that demonstrated lipomatous components and two cases with cartilaginous differentiation. RNA-sequencing revealed fusions involving PHF1 (n = 4) or EPC1 (n = 1) in all (five of five) cases tested, including EPC1::PHC1 and JAZF1::PHF1 fusions, which have not been reported before in ossifying fibromyxoid tumour.</p><p><strong>Conclusion: </strong>These six cases expand the histomorphological spectrum of ossifying fibromyxoid tumour, introducing lipomatous differentiation as a hitherto undocumented feature. Awareness of these rare variants will ensure appropriate diagnosis and clinical management.</p>","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correspondence response to: can patient ancestry influence molecular classifications in myeloid neoplasms? 患者血统是否会影响髓系肿瘤的分子分类?
IF 3.9 2区 医学 Q2 CELL BIOLOGY Pub Date : 2024-12-20 DOI: 10.1111/his.15403
Gregor Hoermann, Yuri Fedoriw, Joseph D Khoury
{"title":"Correspondence response to: can patient ancestry influence molecular classifications in myeloid neoplasms?","authors":"Gregor Hoermann, Yuri Fedoriw, Joseph D Khoury","doi":"10.1111/his.15403","DOIUrl":"https://doi.org/10.1111/his.15403","url":null,"abstract":"","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CD23 expression in lymphoplasmacytic lymphoma: Clinical-pathological and biological correlations. CD23在淋巴浆细胞性淋巴瘤中的表达:临床病理和生物学相关性
IF 3.9 2区 医学 Q2 CELL BIOLOGY Pub Date : 2024-12-20 DOI: 10.1111/his.15401
Marco Pizzi, Nicolò Danesin, Federico Scarmozzino, Martina Pinto, Greta Scapinello, Luisa Santoro, Irene Bertozzi, Gaetano Paride Arcidiacono, Valentina Trimarco, Andrea Visentin, Livio Trentin, Francesco Piazza, Angelo Paolo Dei Tos

Aims: The diagnosis of lymphoplasmacytic lymphoma (LPL) in the bone marrow (BM) is challenged by aberrant phenotypes and by overlapping histological features with marginal zone lymphoma (MZL). To address these issues, we (i) assessed LPL immunophenotype on a large series of BM samples, (ii) drew possible correlations between LPL phenotype and clinical/molecular data and (iii) investigated the role of new phenotypical markers in the differential diagnosis between LPL and MZL.

Materials and methods: The study retrospectively considered 81 clinically annotated LPL diagnosed at Padua University Hospital (Padua, Italy) during a 5-year period. BM findings were correlated with clinical laboratory findings and with MYD88 and CXCR4 mutational status. The obtained results were compared with a series of 77 MZL in the BM, including 46 splenic MZL (SMZL), 14 nodal MZL (NMZL) and 17 extra-nodal MZL (EMZL).

Results: The LPL cohort included 52 males and 29 females (median age at diagnosis = 71 years). Aberrant CD10 and CD5 positivity was documented in 3 of 81 (3.7%) and 13 of 81 (16.1%) cases, respectively. CD23 positivity occurred in 56 of 81 (69.1%) cases, being usually partial/focal. CD23 expression did not correlate with any specific clinical-pathological parameter. Comparison with SMZL, NMZL and EMZL highlighted less frequent splenomegaly, higher serum paraprotein, higher CD23 expression and fewer follicular dendritic cell networks in LPL. A combined clinical-pathological score supported the differential diagnosis between LPL and MZL of any type. The highest diagnostic yield was obtained for the differential diagnosis between LPL and SMZL.

Conclusions: Partial positivity for CD23 is a common feature of LPL in the BM. Together with other clinical and histological parameters, CD23 expression supports the differential diagnosis between LPL and MZL.

目的:骨髓淋巴浆细胞性淋巴瘤(LPL)的诊断受到异常表型和与边缘带淋巴瘤(MZL)重叠的组织学特征的挑战。为了解决这些问题,我们(i)在大量BM样本上评估了LPL的免疫表型,(ii)得出了LPL表型与临床/分子数据之间可能的相关性,(iii)研究了新的表型标记物在LPL和MZL鉴别诊断中的作用。材料和方法:本研究回顾性分析了帕多瓦大学医院(Padua, Italy) 5年期间诊断的81例临床注释的LPL。BM结果与临床实验室结果以及MYD88和CXCR4突变状态相关。将所得结果与BM的77例MZL进行比较,其中脾MZL 46例,淋巴结MZL 14例,淋巴结外MZL 17例。结果:LPL队列包括52名男性和29名女性(诊断时的中位年龄= 71岁)。81例患者中CD10和CD5异常阳性分别为3例(3.7%)和13例(16.1%)。81例病例中有56例(69.1%)出现CD23阳性,通常为部分/局灶性阳性。CD23的表达与任何特定的临床病理参数无关。与SMZL相比,NMZL和EMZL的脾肿大发生率较低,血清副蛋白含量较高,CD23表达较高,滤泡树突状细胞网络较少。临床病理综合评分支持LPL和任何类型MZL的鉴别诊断。鉴别诊断LPL和SMZL的诊断率最高。结论:CD23部分阳性是BM中LPL的共同特征。结合其他临床和组织学参数,CD23表达支持LPL和MZL的鉴别诊断。
{"title":"CD23 expression in lymphoplasmacytic lymphoma: Clinical-pathological and biological correlations.","authors":"Marco Pizzi, Nicolò Danesin, Federico Scarmozzino, Martina Pinto, Greta Scapinello, Luisa Santoro, Irene Bertozzi, Gaetano Paride Arcidiacono, Valentina Trimarco, Andrea Visentin, Livio Trentin, Francesco Piazza, Angelo Paolo Dei Tos","doi":"10.1111/his.15401","DOIUrl":"https://doi.org/10.1111/his.15401","url":null,"abstract":"<p><strong>Aims: </strong>The diagnosis of lymphoplasmacytic lymphoma (LPL) in the bone marrow (BM) is challenged by aberrant phenotypes and by overlapping histological features with marginal zone lymphoma (MZL). To address these issues, we (i) assessed LPL immunophenotype on a large series of BM samples, (ii) drew possible correlations between LPL phenotype and clinical/molecular data and (iii) investigated the role of new phenotypical markers in the differential diagnosis between LPL and MZL.</p><p><strong>Materials and methods: </strong>The study retrospectively considered 81 clinically annotated LPL diagnosed at Padua University Hospital (Padua, Italy) during a 5-year period. BM findings were correlated with clinical laboratory findings and with MYD88 and CXCR4 mutational status. The obtained results were compared with a series of 77 MZL in the BM, including 46 splenic MZL (SMZL), 14 nodal MZL (NMZL) and 17 extra-nodal MZL (EMZL).</p><p><strong>Results: </strong>The LPL cohort included 52 males and 29 females (median age at diagnosis = 71 years). Aberrant CD10 and CD5 positivity was documented in 3 of 81 (3.7%) and 13 of 81 (16.1%) cases, respectively. CD23 positivity occurred in 56 of 81 (69.1%) cases, being usually partial/focal. CD23 expression did not correlate with any specific clinical-pathological parameter. Comparison with SMZL, NMZL and EMZL highlighted less frequent splenomegaly, higher serum paraprotein, higher CD23 expression and fewer follicular dendritic cell networks in LPL. A combined clinical-pathological score supported the differential diagnosis between LPL and MZL of any type. The highest diagnostic yield was obtained for the differential diagnosis between LPL and SMZL.</p><p><strong>Conclusions: </strong>Partial positivity for CD23 is a common feature of LPL in the BM. Together with other clinical and histological parameters, CD23 expression supports the differential diagnosis between LPL and MZL.</p>","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Histopathology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1